PULIKE(SH:603566)2023-10-25 16:00Financial Performance - Total revenue for Q3 2023 was CNY 310,567,619.03, a decrease of 0.92% compared to CNY 313,002,591.87 in the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was CNY 63,062,670.00, an increase of 22.82% from CNY 51,346,891.00 year-on-year[5] - The company reported a year-to-date revenue of CNY 928,544,919.03, representing a 12.25% increase from CNY 827,231,000.00 in the previous year[5] - The revenue from biological products for the first nine months of 2023 was CNY 903,605,793.56, up 13.01% from CNY 799,563,482.51 in the same period last year[9] - Total revenue for the first three quarters of 2023 reached ¥928,544,281.17, an increase of 12.2% compared to ¥827,231,705.37 in the same period of 2022[23] - Net profit for the third quarter of 2023 was ¥179,111,279.58, compared to ¥128,139,567.34 in the same quarter of 2022, representing an increase of 39.8%[24] - The total comprehensive income for the third quarter of 2023 was CNY 179,111,279.58, compared to CNY 128,139,567.34 in the same period of 2022, representing an increase of approximately 39.7%[25] Profitability Metrics - The gross profit margin for Q3 2023 was reported at 20.25%, reflecting a slight increase from the previous year[6] - The basic earnings per share for Q3 2023 was CNY 0.18, an increase of 12.50% compared to CNY 0.16 in the same period last year[6] - Basic and diluted earnings per share for the third quarter were CNY 0.52, up from CNY 0.41 in the previous year, indicating a growth of 26.8%[25] - Net profit attributable to shareholders of the listed company increased by 39.78%[12] Cash Flow and Investments - The company reported a net cash flow from operating activities of CNY 189,293,000.00, an increase of 10.25% from CNY 171,694,000.00 year-on-year[6] - Cash inflow from operating activities for the first three quarters of 2023 was CNY 1,011,662,197.70, a significant increase of 30.8% from CNY 773,361,291.05 in the same period of 2022[27] - The net cash flow from operating activities was CNY 189,293,513.16, compared to CNY 171,694,668.48 in the previous year, reflecting a growth of 10.2%[27] - Cash inflow from investment activities totaled CNY 1,928,700,999.44, a substantial increase from CNY 131,419,647.32 in the same period last year[27] - The net cash flow from investment activities was -CNY 58,714,384.88, an improvement from -CNY 119,807,343.68 in the previous year[27] - Cash flow from financing activities resulted in a net outflow of -CNY 102,206,929.22, compared to a net inflow of CNY 832,833,961.62 in the same period of 2022[28] Assets and Liabilities - The company’s total assets as of the end of the reporting period were CNY 3,346,802,148.67, a decrease of 1.44% from CNY 3,386,568,818.27 at the end of the previous year[6] - The company's total assets as of the end of the third quarter of 2023 amounted to ¥3,346,802,148.67, a slight decrease from ¥3,395,529,763.80 at the end of the previous quarter[21] - Current liabilities totaled ¥570,715,456.25, showing a marginal increase from ¥556,134,350.26 in the previous quarter[20] - The total liabilities of the company as of the end of the third quarter were ¥611,027,035.01, compared to ¥591,555,452.27 in the previous quarter, indicating an increase of 3.4%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,407[14] - The company repurchased 6,854,300 shares, accounting for 1.94% of the total share capital[16] Operational Costs - Total operating costs for the first three quarters of 2023 were ¥739,133,438.26, up from ¥673,073,470.26 in 2022, reflecting a year-over-year increase of 9.8%[23] - Cash paid for purchasing goods and services increased by 62.54% due to payments for materials and equipment[12] - Cash paid for taxes increased by 94.20% primarily due to the expiration of tax policies from 2022[12] - Cash paid for dividends and profit distribution increased by 84.76% due to higher profit distribution[12] Research and Development - Research and development expenses for the first three quarters of 2023 were ¥61,158,439.34, an increase from ¥49,289,650.27 in the same period of 2022, reflecting a growth of 24.1%[23] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies and products to drive future growth[29]